Zevra Therapeutics, Inc. (ZVRA)
8.49
-0.14
(-1.62%)
USD |
NASDAQ |
Jan 09, 16:00
8.50
+0.01
(+0.12%)
After-Hours: 20:00
Zevra Therapeutics Research and Development Expense (Quarterly): 3.432M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| XOMA Royalty Corp. | 0.069M |
| Verastem, Inc. | 28.99M |
| ADMA Biologics, Inc. | 1.528M |
| Akebia Therapeutics, Inc. | 14.63M |
| NovaBay Pharmaceuticals, Inc. | -- |